Nicotinamide N-methyltransferase Inhibitor Screening Kit II (F)

MILPITAS, Calif. - April 13, 2021 - PRLog -- Nicotinamide N-methyltransferase (NNMT; EC 2.1.1.1) is an important cytosolic enzyme. It catalyzes the N-methylation of nicotinamide by transferring a methyl group from S-adenosyl-L-methionine (SAM) to nicotinamide resulting in the formation of 1-methyl-nicotinamide (MNA) and S-adenosyl-L-homocysteine. NNMT plays a significant role in the regulation of metabolic pathways in tissues such as adipose and liver as well as in cancer cells. Abnormal NNMT expression and activity has been implicated in a number of chronic diseases including cardiovascular diseases, cancer, obestity, diabetes, osteoarthritis, Parkinson's disease etc. Therefore, small molecule inhibitors of NNMT could be beneficial in developing therapeutics for diseases characterized by abnormal NNMT activity.

BioVision's Nicotinamide N-methyltransferase inhibitor screening Kit II is a non-coupled, plate-based fluorometric assay. The assay utilizes a selective NNMT substrate that is methylated by SAM to generate a fluorescent product, measured at Ex/Em = 320/420 nm. In the presence of 1-Methylnicotinamide, a NNMT inhibitor, the enzymatic activity is inhibited thereby resulting in a reduced fluorescent signal. The kit provids a one-step, rapid, reliable test for high-throughput screening of NNMT inhibitors.

Figures. a) NNMT enzyme activity in the presence or absence of MNA. b) NNMT enzyme activity in the presence or absence of DMSO. c) Inhibition of NNMT enzyme activity by MNA. IC50 of MNA was calculated as 25.45±2.5 μM. Assays were performed following the kit protocol.

For more information on this Assay kit Cat# K2081, Visit: https://bit.ly/3dfVWbW